Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments (2020 - 2025)

Silence Therapeutics' Short-term Investments history spans 6 years, with the latest figure at $73.8 million for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 183.94% to $73.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.8 million, a 183.94% increase, with the full-year FY2025 number at $73.8 million, up 183.94% from a year prior.
  • Short-term Investments hit $73.8 million in Q4 2025 for Silence Therapeutics, up from $20.2 million in the prior quarter.
  • Over the last five years, Short-term Investments for SLN hit a ceiling of $87.1 million in Q3 2024 and a floor of $334707.7 in Q3 2022.
  • Historically, Short-term Investments has averaged $27.3 million across 5 years, with a median of $19.6 million in 2023.
  • Biggest five-year swings in Short-term Investments: crashed 98.16% in 2023 and later skyrocketed 24112.36% in 2024.
  • Tracing SLN's Short-term Investments over 5 years: stood at $405751.2 in 2021, then surged by 4620.03% to $19.2 million in 2022, then crashed by 98.16% to $352487.1 in 2023, then soared by 7277.29% to $26.0 million in 2024, then surged by 183.94% to $73.8 million in 2025.
  • Business Quant data shows Short-term Investments for SLN at $73.8 million in Q4 2025, $20.2 million in Q3 2025, and $72.4 million in Q2 2025.